Skip to main content

Advertisement

SpringerLink
Log in

Do Angiotensin Receptor Blockers Protect Against Alzheimer’s Disease?

  • Current Opinion
  • Published:
Drugs & Aging Aims and scope Submit manuscript

Abstract

Because growing evidence suggests that angiotensin II receptor blockers (ARBs) effectively inhibit oxidative stress, amyloid beta protein (Aβ) metabolism, and tau phosphorylation in animal brains, ARBs are considered to be a potential candidate for the treatment of Alzheimer’s disease (AD). Consistent with such basic studies, two recent observational studies and a small prospective, randomized, open-label trial have shown the effectiveness of ARBs in preventing AD and/or slowing its progression. Nonetheless, large clinical trials have not shown their effectiveness, but their results are debatable because of short follow-up durations and heterogeneity of the cognition assessments used in the studies. Because a recent analysis of the Honolulu-Asia Aging study showed that abnormalities of the serum Aβ level begin approximately 15 years before the diagnosis of AD, long-term clinical trials assessing dementia as a primary endpoint with sensitive measurements of cognition and brain imaging techniques will clarify the effectiveness of ARBs in AD treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Birks J. Cholinesterase inhibitors for Alzheimer’s disease. Cochrane Database Syst Rev. 2006(1):CD005593.

  2. Farrimond LE, Roberts E, McShane R. Memantine and cholinesterase inhibitor combination therapy for Alzheimer’s disease: a systematic review. BMJ Open. 2012;2(3).

  3. Mielke MM, Leoutsakos JM, Corcoran CD, Green RC, Norton MC, Welsh-Bohmer KA, et al. Effects of Food and Drug Administration-approved medications for Alzheimer’s disease on clinical progression. Alzheimers Dement. 2012;8(3):180–7.

    Article  PubMed  CAS  Google Scholar 

  4. de la Torre JC. Vascular risk factor detection and control may prevent Alzheimer’s disease. Ageing Res Rev. England: 2010 Elsevier Ireland Ltd; 2010. p. 218–25.

  5. de la Torre JC. Preface: physiopathology of vascular risk factors in Alzheimer’s disease. J Alzheimers Dis. 2012;32(3):517–8.

    PubMed  Google Scholar 

  6. Peila R, White LR, Masaki K, Petrovitch H, Launer LJ. Reducing the risk of dementia: efficacy of long-term treatment of hypertension. Stroke. 2006;37(5):1165–70.

    Article  PubMed  Google Scholar 

  7. Petrovitch H, White LR, Izmirilian G, Ross GW, Havlik RJ, Markesbery W, et al. Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study. Neurobiol Aging. 2000;21(1):57–62.

    Google Scholar 

  8. Shah NS, Vidal JS, Masaki K, Petrovitch H, Ross GW, Tilley C, et al. Midlife blood pressure, plasma beta-amyloid, and the risk for Alzheimer disease: the Honolulu Asia Aging Study. Hypertension. 2012;59(4):780–6.

    Article  PubMed  CAS  Google Scholar 

  9. Ninomiya T, Ohara T, Hirakawa Y, Yoshida D, Doi Y, Hata J, et al. Midlife and late-life blood pressure and dementia in Japanese elderly: the Hisayama study. Hypertension. 2011;58(1):22–8.

    Google Scholar 

  10. Wang J, Ho L, Chen L, Zhao Z, Zhao W, Qian X, et al. Valsartan lowers brain beta-amyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease. J Clin Invest. 2007;117(11):3393–402.

    Article  PubMed  CAS  Google Scholar 

  11. Savaskan E, Hock C, Olivieri G, Bruttel S, Rosenberg C, Hulette C, et al. Cortical alterations of angiotensin converting enzyme, angiotensin II and AT1 receptor in Alzheimer’s dementia. Neurobiol Aging. 2001;22(4):541–6.

    Google Scholar 

  12. Li WZ, Li WP, Yao YY, Zhang W, Yin YY, Wu GC, et al. Glucocorticoids increase impairments in learning and memory due to elevated amyloid precursor protein expression and neuronal apoptosis in 12-month old mice. Eur J Pharmacol. 2010;628(1–3):108–15.

    Article  PubMed  CAS  Google Scholar 

  13. Tian M, Zhu D, Xie W, Shi J. Central angiotensin II-induced Alzheimer-like tau phosphorylation in normal rat brains. FEBS Lett. 2012;586(20):3737–45.

    Google Scholar 

  14. Takeda S, Sato N, Takeuchi D, Kurinami H, Shinohara M, Niisato K, et al. Angiotensin receptor blocker prevented beta-amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension. 2009;54(6):1345–52.

    Article  PubMed  CAS  Google Scholar 

  15. Didion SP, Kinzenbaw DA, Faraci FM. Critical role for CuZn-superoxide dismutase in preventing angiotensin II-induced endothelial dysfunction. Hypertension. 2005;46(5):1147–53.

    Article  PubMed  CAS  Google Scholar 

  16. Kazama K, Anrather J, Zhou P, Girouard H, Frys K, Milner TA, et al. Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circ Res. 2004;95(10):1019–26.

    Article  PubMed  CAS  Google Scholar 

  17. Gorelick PB, Scuteri A, Black SE, Decarli C, Greenberg SM, Iadecola C, et al. Vascular contributions to cognitive impairment and dementia: a statement for healthcare professionals from the american heart association/american stroke association. Stroke. 2011;42(9):2672–713.

    Article  PubMed  Google Scholar 

  18. Miners JS, Ashby E, Van Helmond Z, Chalmers KA, Palmer LE, Love S, et al. Angiotensin-converting enzyme (ACE) levels and activity in Alzheimer’s disease, and relationship of perivascular ACE-1 to cerebral amyloid angiopathy. Neuropathol Appl Neurobiol. 2008;34(2):181–93.

    Article  PubMed  CAS  Google Scholar 

  19. Wayner MJ, Armstrong DL, Polan-Curtain JL, Denny JB. Ethanol and diazepam inhibition of hippocampal LTP is mediated by angiotensin II and AT1 receptors. Peptides. 1993;14(3):441–4.

    Google Scholar 

  20. Wayner MJ, Polan-Curtain J, Armstrong DL. Dose and time dependency of angiotensin II inhibition of hippocampal long-term potentiation. Peptides. 1995;16(6):1079–82.

    Article  PubMed  CAS  Google Scholar 

  21. Barnes JM, Barnes NM, Costall B, Coughlan J, Kelly ME, Naylor RJ, et al. Angiotensin-converting enzyme inhibition, angiotensin, and cognition. J Cardiovasc Pharmacol. 1992;19(Suppl 6):S63–71.

    Article  PubMed  CAS  Google Scholar 

  22. Danielyan L, Klein R, Hanson LR, Buadze M, Schwab M, Gleiter CH, et al. Protective effects of intranasal losartan in the APP/PS1 transgenic mouse model of Alzheimer disease. Rejuvenation Res. 2010;13(2–3):195–201.

    Google Scholar 

  23. Zhu D, Shi J, Zhang Y, Wang B, Liu W, Chen Z, et al. Central angiotensin II stimulation promotes beta amyloid production in Sprague Dawley rats. PLoS One. 2011;6(1):e16037.

    Article  PubMed  CAS  Google Scholar 

  24. Mogi M, Li JM, Tsukuda K, Iwanami J, Min LJ, Sakata A, et al. Telmisartan prevented cognitive decline partly due to PPAR-gamma activation. Biochem Biophys Res Commun. 2008;375(3):446–9.

    Article  PubMed  CAS  Google Scholar 

  25. Sastre M, Dewachter I, Rossner S, Bogdanovic N, Rosen E, Borghgraef P, et al. Nonsteroidal anti-inflammatory drugs repress beta-secretase gene promoter activity by the activation of PPARgamma. Proc Natl Acad Sci U S A. 2006;103(2):443–8.

    Article  PubMed  CAS  Google Scholar 

  26. Kehoe PG, Miners S, Love S. Angiotensins in Alzheimer’s disease - friend or foe? Trends Neurosci. 2009;32(12):619–28.

    Google Scholar 

  27. Hemming ML, Selkoe DJ. Amyloid beta-protein is degraded by cellular angiotensin-converting enzyme (ACE) and elevated by an ACE inhibitor. J Biol Chem. 2005;280(45):37644–50.

    Article  PubMed  CAS  Google Scholar 

  28. Oba R, Igarashi A, Kamata M, Nagata K, Takano S, Nakagawa H. The N-terminal active centre of human angiotensin-converting enzyme degrades Alzheimer amyloid beta-peptide. Eur J Neurosci. 2005;21(3):733–40.

    Article  PubMed  Google Scholar 

  29. Yamada K, Uchida S, Takahashi S, Takayama M, Nagata Y, Suzuki N, et al. Effect of a centrally active angiotensin-converting enzyme inhibitor, perindopril, on cognitive performance in a mouse model of Alzheimer’s disease. Brain Res. 2010;1352:176–86.

    Article  PubMed  CAS  Google Scholar 

  30. Dong YF, Kataoka K, Tokutomi Y, Nako H, Nakamura T, Toyama K, et al. Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer’s disease. FASEB J. 2011;25(9):2911–20.

    Article  PubMed  CAS  Google Scholar 

  31. Ferrington L, Miners JS, Palmer LE, Bond SM, Povey JE, Kelly PA, et al. Angiotensin II-inhibiting drugs have no effect on intraneuronal Aβ or oligomeric Aβ levels in a triple transgenic mouse model of Alzheimer’s disease. Am J Transl Res. 2011;3(2):197–208.

    PubMed  CAS  Google Scholar 

  32. Ferrington L, Palmer LE, Love S, Horsburgh KJ, Kelly PA, Kehoe PG. Angiotensin II-inhibition: effect on Alzheimer’s pathology in the aged triple transgenic mouse. Am J Transl Res. 2012;4(2):151–64.

    PubMed  CAS  Google Scholar 

  33. Li NC, Lee A, Whitmer RA, Kivipelto M, Lawler E, Kazis LE, et al. Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ. 2010;340:b5465.

    Article  PubMed  Google Scholar 

  34. Yusuf S, Teo KK, Pogue J, Dyal L, Copland I, Schumacher H, et al. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59.

    Article  PubMed  CAS  Google Scholar 

  35. Davies NM, Kehoe PG, Ben-Shlomo Y, Martin RM. Associations of anti-hypertensive treatments with Alzheimer’s disease, vascular dementia, and other dementias. J Alzheimers Dis. 2011;26(4):699–708.

    PubMed  Google Scholar 

  36. Hanon O, Berrou JP, Negre-Pages L, Goch JH, Nadhazi Z, Petrella R, et al. Effects of hypertension therapy based on eprosartan on systolic arterial blood pressure and cognitive function: primary results of the Observational Study on Cognitive function And Systolic Blood Pressure Reduction open-label study. J Hypertens. 2008;26(8):1642–50.

    Article  PubMed  CAS  Google Scholar 

  37. Lithell H, Hansson L, Skoog I, Elmfeldt D, Hofman A, Olofsson B, et al. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens. 2003;21(5):875–86.

    Article  PubMed  CAS  Google Scholar 

  38. Diener HC, Sacco RL, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Effects of aspirin plus extended-release dipyridamole versus clopidogrel and telmisartan on disability and cognitive function after recurrent stroke in patients with ischaemic stroke in the Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial: a double-blind, active and placebo-controlled study. Lancet Neurol. 2008;7(10):875–84.

    Article  PubMed  CAS  Google Scholar 

  39. Barnes DE, Yaffe K. The projected effect of risk factor reduction on Alzheimer’s disease prevalence. Lancet Neurol. 2011;10(9):819–28.

    Article  PubMed  Google Scholar 

  40. Petrella RJ, Shlyakhto E, Konradi AO, Berrou JP, Sedefdjian A, Pathak A. Blood pressure responses to hypertension treatment and trends in cognitive function in patients with initially difficult-to-treat hypertension: a retrospective subgroup analysis of the Observational Study on Cognitive Function and SBP Reduction (OSCAR) study. J Clin Hypertens (Greenwich). 2012;14(2):78–84.

    Article  CAS  Google Scholar 

  41. Kume K, Hanyu H, Sakurai H, Takada Y, Onuma T, Iwamoto T. Effects of telmisartan on cognition and regional cerebral blood flow in hypertensive patients with Alzheimer’s disease. Geriatr Gerontol Int. 2012;12(2):207–14.

    Article  PubMed  Google Scholar 

  42. Hajjar I, Hart M, Chen YL, Mack W, Milberg W, Chui H, et al. Effect of antihypertensive therapy on cognitive function in early executive cognitive impairment: a double-blind randomized clinical trial. Arch Intern Med. 2012;172(5):442–4.

    Article  PubMed  Google Scholar 

  43. Hajjar I, Hart M, Milberg W, Novak V, Lipsitz L. The rationale and design of the antihypertensives and vascular, endothelial, and cognitive function (AVEC) trial in elderly hypertensives with early cognitive impairment: role of the renin angiotensin system inhibition. BMC Geriatr. 2009;9:48.

    Article  PubMed  Google Scholar 

Download references

Acknowledgments

No external funding was used in the preparation of this review. The authors have declared no conflicts of interest that might be relevant to the content of this review.

Author information

Authors and Affiliations

  1. Division of Vascular Medicine and Epigenetics, Department of Child Development, United Graduate School of Child Development, Osaka University, Kanazawa University and Hamamatsu University School of Medicine, Suita, Japan

    Hitomi Kurinami, Munehisa Shimamura & Hironori Nakagami

  2. Department of Clinical Gene Therapy, Osaka University, Graduate School of Medicine, 2-2 Yamada-oka, Suita, Osaka, 565-0871, Japan

    Naoyuki Sato & Ryuichi Morishita

Authors
  1. Hitomi Kurinami
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Munehisa Shimamura
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Naoyuki Sato
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Hironori Nakagami
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ryuichi Morishita
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryuichi Morishita.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Kurinami, H., Shimamura, M., Sato, N. et al. Do Angiotensin Receptor Blockers Protect Against Alzheimer’s Disease?. Drugs Aging 30, 367–372 (2013). https://doi.org/10.1007/s40266-013-0071-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40266-013-0071-2

Keywords

Search

Navigation